Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.

Pharmaceutical statistics - 1 Jan 2000

Wang Sue-Jane, O'Neill Robert T, Hung H M James

Abstract excerpt

With the advances in human genomic/genetic studies, the clinical trial community gradually recognizes that phenotypically homogeneous patients may be heterogeneous at the genomic level. The genomic technology brings a possible avenue for developing a genomic (composite) biomarker to predict a genomically responsive patient subset that may have a (much) higher likelihood of benefiting from a treatment. Randomized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Genomics
Share to Likelihood Functions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Genetic

Share to Monte Carlo Method

Share to Phenotype

Share to Randomized Controlled Trials as Topic

Share to Treatment Outcome

Source

Identifiers

PMID: 17688238
DOI: 10.1002/pst.300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.PMID 17688238Read ↗

On the efficiency of targeted clinical trials.Semantic proximity Read ↗

Confident identification of subgroups from SNP testing in RCTs with binary outcomes.Semantic proximity Read ↗

Prospective–Retrospective Biomarker Analysis for Regulatory Consideration: white Paper from the Industry Pharmacogenomics Working GroupSemantic proximity Read ↗

Extending Inferences From A Real-world Clinico-Genomic Database Non-Small Cell Lung Cancer Sample To The Underlying Target Population Using Combined Information From Cancer RegistrationsSemantic proximity Read ↗

Extending Inferences From A Real-world Clinico-Genomic Database Non-Small Cell Lung Cancer Sample To The Underlying Target Population Using Combined Information From Cancer RegistrationsSemantic proximity Read ↗

Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial.Semantic proximity Read ↗

Rare genetic variants and treatment response: sample size and analysis issues.Semantic proximity Read ↗

Integrating genetic data in target trial emulations improves their design and informs the value of polygenic scores for prognostic and predictive enrichmentSemantic proximity Read ↗

Computational Phenomapping of Randomized Clinical Trials to Enable Assessment of their Real-world Representativeness and Personalized InferenceSemantic proximity Read ↗

Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.Semantic proximity Read ↗

Finding associations in a heterogeneous setting: Statistical test for aberration enrichmentSemantic proximity Read ↗

Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.